Patents Examined by Anne Marie S. Wehbe
  • Patent number: 10463029
    Abstract: This disclosure relates to a rodent model of Steel Syndrome. Disclosed herein are genetically modified rodent animals that carry a mutation in an endogenous rodent Col27a1 gene, equivalent to a mutation in humans causing Steel Syndrome.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: November 5, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Claudia Gonzaga-Jauregui, Chia-Jen Siao, Harikiran Nistala, Kalyan C. Nannuru
  • Patent number: 10456480
    Abstract: This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: October 29, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Eric M. Poeschla, Roman A. Barraza
  • Patent number: 10448622
    Abstract: The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody ? light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the nonhuman animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: October 22, 2019
    Assignees: E. R. Squibb & Sons, L.L.C., Kyowa Hakko Kirin Co., Ltd
    Inventors: Yoshimi Kuroiwa, Kazuma Tomizuka, Hitoshi Yoshida, Isao Ishida
  • Patent number: 10435669
    Abstract: The invention relates to the field of microbiology, specifically to a bacteriophage, polypeptide and a corresponding polynucleotide, a nucleic acid molecule and/or vector and/or cell comprising such polynucleotide, a composition comprising said bacteriophage, polypeptide, polynucleotide, construct, vector and/or cell, preferably for preventing, treating or diagnosing contamination with and/or a condition in an individual related to Salmonella. The invention further relates to an antimicrobial composition for medical use or for use as a food additive or as a disinfectant, or for detecting bacteria, preferably in a diagnostic application, wherein said antimicrobial composition comprises a bacteriophage, polypeptide, corresponding polynucleotide, construct and/or vector and/or cell comprising such polypeptide and/or composition according to the present invention.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: October 8, 2019
    Assignee: MICREOS B.V.
    Inventors: Martin Johannes Loessner, Steven Hagens, Albert Johannes Hendrikus Slijkhuis, Jochen Achim Klumpp, Roger Marti
  • Patent number: 10435441
    Abstract: Disclosed herein are Htt repressors and methods and compositions for use of these Htt repressors.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: October 8, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Steven Froelich, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Bryan Zeitler, H. Steve Zhang
  • Patent number: 10433527
    Abstract: The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: October 8, 2019
    Assignees: Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in Biomedicine (IRB)
    Inventors: Richard Flavell, Markus Manz, Anthony Rongvaux, Till Strowig, Tim Willinger, Andrew J. Murphy, Sean Stevens, George Yancopoulos
  • Patent number: 10426146
    Abstract: Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRP? gene. Genetically modified mice are described, including mice that express a human or humanized SIRP? protein from an endogenous SIRP? locus.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: October 1, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Andrew J. Murphy, O. Gavin Thurston, Bindu Varghese, Cagan Gurer
  • Patent number: 10412940
    Abstract: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that present a choice of two human light chain variable gene segments such that the immunoglobulin light chains expresses by the mouse comprise one of the two human light chain variable gene segments. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: September 17, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: John McWhirter, Lynn Macdonald, Sean Stevens, Andrew J. Murphy
  • Patent number: 10376567
    Abstract: This invention provides novel carbonic anhydrase (CAIX) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e.g. vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a CAIX antigenic marker. The novel CAIX variant and related compositions are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: August 13, 2019
    Assignee: The Regents of the University of California
    Inventors: Zhenhua Li, Arie S. Belldegrun
  • Patent number: 10378007
    Abstract: Methods for improving or modulating targeting specificity of TALE proteins by introducing alternative RVDs into their modular nucleic acid binding domains. Polynucleotides encoding TALE proteins having alternative targeting specificity towards a nucleic acid target sequence. TALE proteins having alternative targeting specificity towards a nucleic acid target sequence and methods of making and using them.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: August 13, 2019
    Assignee: CELLECTIS
    Inventors: Alexandre Juillerat, Philippe Duchateau
  • Patent number: 10314298
    Abstract: Genetically modified non-human animals comprising a human or humanized interleukin-7 (IL-7) gene. Cells, embryos, and non-human animals comprising a human or humanized IL-7 gene. Rodents that express human or humanized IL-7 protein. Genetically modified mice that comprise a human or humanized IL-7-encoding gene in their germline, wherein the human or humanized IL-7-encoding gene is under control of endogenous mouse IL-7 regulatory sequences.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: June 11, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventor: Andrew J. Murphy
  • Patent number: 10307461
    Abstract: Disclosed is a method of treating or preventing polycystic kidney disease (PKD) by administration of neutrophil geleatinase-associated lipocalin (Ngal) protein. Also, a transgenic non-human animal model is established to investigate the effect of overexpression of exogenous Ngal on PKD progression.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: June 4, 2019
    Assignee: NATIONAL TAIWAN NORMAL UNIVERSITY
    Inventors: Hsiu-Mei Hsieh, Yi-Ren Wang, Si-Tse Jiang, Wen-Yih Jeng, Yuan-Yow Chiou
  • Patent number: 10299467
    Abstract: The present invention relates to the use of a genetically modified non-human animal as an animal model for obesity or obesity-related disorders, wherein the amount of Lysine-specific Demethylase 1 (LSD1) in at least one tissue or at least one cell type of said animal is reduced.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: May 28, 2019
    Assignee: UNIVERSITAETSKLINIKUM FREIBURG
    Inventors: Roland Schüle, Delphine Duteil, Eric Metzger, Thomas Günther
  • Patent number: 10301388
    Abstract: Described herein are human antibody agents and multi-specific binding agents that specifically bind human CD 19, in particular, native human CD 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by CD 19 expression, in particular, B cell lymphomas and leukemias.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: May 28, 2019
    Assignee: Eureka Therapeutics, Inc.
    Inventors: Hong Liu, Jingwei Lu, Zhiyuan Yang, Li Long, Neal Cheng
  • Patent number: 10301614
    Abstract: The present invention relates to polypeptides and more particularly to Transcription Activator-Like Effector derived proteins that allow to efficiently target and/or process nucleic acids. Particularly, the present invention reports the characterization of TALE derived proteins that can efficiently target methylated DNA. The present invention more specifically relates to TALE derived proteins that allow activation of methylated promoters responsible for gene silencing.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 28, 2019
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, Julien Valton
  • Patent number: 10287608
    Abstract: Provided herein are compositions and methods for selective expression of a transgene. Compositions and methods for selective expression of a transgene comprise one or more human regulatory elements, which, when operably linked to a transgene, can facilitate selective expression of a transgene (e.g., cell-type selective expression) in a target cell as compared to at least one or more non-target cells.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: May 14, 2019
    Assignee: Encoded Therapeutics, Inc.
    Inventors: Stephanie Tagliatela, Andrew Young, Szu-Ying Chen, Kartik Ramamoorthi, David Oberkofler
  • Patent number: 10287607
    Abstract: Provided herein are compositions and methods for selective expression of a transgene. Compositions and methods for selective expression of a transgene comprise one or more human regulatory elements, which, when operably linked to a transgene, can facilitate selective expression of a transgene (e.g., cell-type selective expression) in a target cell as compared to at least one or more non-target cells.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: May 14, 2019
    Assignee: Encoded Therapeutics, Inc.
    Inventors: Stephanie Tagliatela, Andrew Young, Szu-Ying Chen, Kartik Ramamoorthi, David Oberkofler
  • Patent number: 10251376
    Abstract: This document relates to methods and materials involved in the removal of senescent cells within a mammal. For example, transgenic non-human animals that can be induced to delete senescent cells are provided.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: April 9, 2019
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: James L. Kirkland, Tamar Tchkonia, Jan M. A. van Deursen, Darren J. Baker
  • Patent number: 10238093
    Abstract: Mice, embryos, cells, and tissues having a restricted immunoglobulin heavy chain locus and an ectopic sequence encoding one or more ADAM6 proteins are provided. In various embodiments, mice are described that have humanized endogenous immunoglobulin heavy chain loci and are capable of expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof that is functional in a male mouse. Mice, embryos, cells, and tissues having an immunoglobulin heavy chain locus characterized by a single human VH gene segment, a plurality of human DH gene segments and a plurality of human JH gene segments and capable expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof are also provided.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: March 26, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, John McWhirter, Sean Stevens, Andrew J. Murphy
  • Patent number: 10231998
    Abstract: A method of radiation-free hematopoietic stem cell (HSC) transplantation comprises administering to a mammalian subject one or two doses of 2 to 10 mg/kg body weight of a purine base analog, such as 6TG as a pre-conditioning step. The method further comprises engrafting into the subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs within 48 to 72 hours of the pre-conditioning step; and administering to the subject about 1 to 5 mg/kg of the purine base analog every two to four days for two to eight weeks following the engrafting step. The method is performed in the absence of pre-conditioning via radiation. The subject is therefore not treated with myeloablative radiation in preparation for transplantation, and thus the subject is free of myeloablative radiation-induced toxicity.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: March 19, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Noriyuki Kasahara, Robert H. Schiestl, Katrin Hacke, Akos Szakmary, Gay M. Crooks